Amgen (Nasdaq: AMGN) announces the following top-line results for XGEVA (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE